Kyverna Therapeutics, Inc. Common Stock KYTX
i
Market datapartial · fetched 2026-11-07T21:45:07.106Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:26:28.887138765Z
FundamentalsAlpha Vantage · unavailable
Kyverna Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | ||||||
| 45Δ | ||||||
| 50Δ | 5.29 | 191.9% | 12.1% | |||
| 55Δ | 5.59 | 189.8% | 10.7% | |||
| 60Δ | 4.62 | 193.3% | 12.8% | 5.89 | 187.6% | 9.2% |
| 65Δ | 4.30 | 206.7% | 11.2% | 6.18 | 185.4% | 7.8% |
| 70Δ | 3.99 | 220.1% | 9.6% | 6.48 | 183.2% | 6.4% |
| 75Δ | 3.67 | 233.5% | 8.0% | |||
| 80Δ | 3.36 | 246.9% | 6.3% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.29
- IV
- 191.9%
- B/E move
- 12.1%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.59
- IV
- 189.8%
- B/E move
- 10.7%
60Δ
- Pseudo strike
- 4.62
- IV
- 193.3%
- B/E move
- 12.8%
- Pseudo strike
- 5.89
- IV
- 187.6%
- B/E move
- 9.2%
65Δ
- Pseudo strike
- 4.30
- IV
- 206.7%
- B/E move
- 11.2%
- Pseudo strike
- 6.18
- IV
- 185.4%
- B/E move
- 7.8%
70Δ
- Pseudo strike
- 3.99
- IV
- 220.1%
- B/E move
- 9.6%
- Pseudo strike
- 6.48
- IV
- 183.2%
- B/E move
- 6.4%
75Δ
- Pseudo strike
- 3.67
- IV
- 233.5%
- B/E move
- 8.0%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 3.36
- IV
- 246.9%
- B/E move
- 6.3%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 177.57% |
Biotechnology
KZIA
Description unavailable
More →LBRX
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.…
More →LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the…
More →LEGN
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in…
More →LENZ
LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders, specifically targeting critical…
More →LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs…
More →